ROCHE DIAGNOSTICS partners with ISL to expand TROP T Rapid assay in India
Troponin-T is used to measure damage to the heart muscle and to differentiate between non- cardiac chest pains and heart attacks. Roche Diagnostics India Pvt. Ltd. enters into an agreement with Ind-Swift Limited; a Chandigarh based pharmaceutical company to promote its test for detecting heart attack, TROP T rapid assay, in India. Roche Diagnostics India Pvt. Ltd. is part of Roche Group, a worldwide leader in the field of Medical Diagnostics and Pharmaceuticals. Roche Diagnostids' TROP T rapid assay is a point of care test which can detect whether a patient is having a heart attack through a simple whole blood test. Troponin-T is used to measure damage to the heart muscle and to differentiate between non-cardiac chest pains and heart attacks. The TROP T rapid assay gives a reliable qualitative result within 15 minutes. Ind-Swift Ltd. has a Cardio Specific Field Force, CARDIASWIFT which has been marketing cardio & anti-diabetic products for the last 8-10 years. Over the years, CARDIASWIFT has established a sound presence in the minds of cardiac and diabetic specialists and consulting physicians. Ind-Swift Limited will promote TROP T to cardiologists / diabectologists / consulting physicians/general practitioners all over the country with its 225 Strong Field Force. This collaboration with Roche Diagnostics India Pvt. Ltd. will give ISL a big chance to develop a strong presence in the cardiac field with some of the most established and renowned specialists and hospitals", said an elated Dr. Gopal Munjal, M.D & C.E.0, Ind-Swift Group. Speaking on the occasion, Dr. Bhuwnesh Agrawal, Chairman and Managing Director, Roche Diagnostics India and South Asia said, "With a strong commercial partner like Ind-Swift Limited we are confident to penetrate in our target markets and reach out to doctors and patients throughout India and therewith reduce the burden of cardiovascular mortality in our country".
Reforms Espoused In Education System
Polytechnic education and industrial training commissioner Mrs. Usha R Sharma addressing a gathering during a panel discussion at PHD Chamber in Sec-31, Chandigarh, on Friday. A daylong discussion on the subject ‘Are Reforms required in the Education System in India’ organised by the Indo-Swift evoked thought-provoking and pragmatic deliberations. Stressing the need to give education a broader connotation than it being mere literacy, the speakers, most of them educationists, supported the idea of finishing school of education. Mrs. Usha R Sharma, commissioner, polytechnic education and industrial training, chaired the function. The other panelists included Dr. SS Gill, vice-chancellor, Baba Farid University of Health Sciences;Mr. DK Dhawan, professor of department of biophysics, Panjab University; and Videocon vice-president Mr. Prem Ojha. Mr.Vivek Atray, additional transport commissioner, Haryana, was the moderator for the event. Mrs. Usha advocated counseling of the students at an initial stage in schools itself, in terms of the career option they wanted to choose. "Proper education and career of choice would enhance students’ productivity," she added. Mr.Atray said the purpose of education is to ultimately prepare students to compete and grow in the professional world so it should involve real-world exposure and activities. Mr.Ojha said practical and feasible ways for better education are by arrainging frequent interactions with experts or role models from industry or other fields. Mr.Dhawan said foreign direct investments must be encouraged in educational institutes for exposure to fair competition and international faculty. Dr. G Munjal, managing director and CEO, Ind-Swift, espoused the need for finishing schools where the students can be transformed into the best product in terms of individual personalities and contributing elements to society. He concluded the discussion by saying that stern rules and regulations and their strict implementation could usher in positive results in government and private educational institutes. The purpose of education is to ultimately prepare students to compete in professional world, so it should involve real-world exposure. - Vivek Atray

---

---

Ind-Swift project gets Japan govt's nod

BS Reporter / New Delhi/ Chandigarh February 22, 2011, 0:07 IST

Pharma major Ind-Swift Laboratories got the Pharmaceutical and Medical Devices Agency (PMDA) approval from the Japan government for Pioglitazone and Risedronate Sodium to be manufactured at its facilities at Derabassi (Punjab). With this achievement, it has become the first Indian company to get Japanese government’s approval without any observations.
Speaking on the achievement the company’s Vice-Chairman  N R Munjal said, “The company has high regulatory standards where its facilities are already approved by USFDA/TGA/COS/KFDA and with this approval for Pioglitazone which is an anti-diabetic drug with market size worth $2.8 billion and Risedronate Sodium a drug for Osteoporosis with market size worth $1.6 billion, the company is aiming at capturing 15-20 per cent of the market share of these products by 2013”.
For the first time, a large number of drugs patented by Japanese companies are going off patent. With the healthcare market size of $350 billion and only $13 billion worth of pharma product imports, Japan is a promising market for the Indian Pharma manufacturers.
The rapid pace of ageing population and the high healthcare expenditures associated with it are also increasing the popularity of generics in Japan. Japan’s Pharma imports from India are currently less than $10 million and these factors are likely to boost the export prospects.
“We are in the advance stage of negotiations to supply commercial quantities of these products to the Japanese market and the free trade pact between India and Japan will further strengthen the company’s export revenues,” Munjal added.
The Company has already filed four drug master files (DMFs) in Japan including that of Atorvastatin, a 12-billion market drug, PMDA approval for these products is expected shortly, which will take the total approved products to six. Ind-Swift Laboratories Limited has also filed 302 DMFs so far with various regulatory Authorites including four DMFs filed in Japan.
Company cloaked a turnover of Rs 714.32 crore during the nine months ended December 31, 2010, as against Rs 579.84 crore in the similar period in 2009. The company earned a net profit of Rs 61.22 crore in the first nine months against the net profit of Rs 57 crore earned in the financial year ended March, 2010.

---

---

Ind Swift to start college in UK

Chandigarh March 29, 2011, 0:08 IST

Swift Fundamental Research and Education Society (SFRES), the education arm for the Rs 1,600-crore Ind Swift group (manufacturer as well as exporter of Active Pharmaceutical Ingredients (API) and finished doses) is geared to venture in global education with the plan of setting up of a college in the United Kingdom.
Ind Swift group CEO Dr. G Munjal maintained this was the first foray by SFRES on a global scale for which the group will be investing Rs 15 crore.
Dr.Munjal maintained he had identified a building in Birmingham from where Swift Group of Colleges would be starting their courses later this year. The deal for the shortlisted 7,500 sq feet building in Birmingham is expected to be finalised this week.
UK has been a preferred destination for the company primarily because the country is considered a preferred education spot amongst students worldwide. The college, which would be offering 600 seats to start with, would introduce fundamental courses and basic skill development courses for the technical field, the first session for which is likely to commence later this year.
The skill development courses to be introduced in the college will be aimed at catering to the skill requirement needs of the company. The demand for skilled manpower has been firming up, not only nationally but on the global platform as well. Later on, courses like clinical research and innovation would be introduced.
SFRES, which at present manages Swift group of colleges, already has Pharma, nursing, management and engineering colleges in Punjab. The group had diversified into the education sector few years ago and had announced an investment of Rs 500 crore in the education sector.
Already, Rs 75 crore has been invested in the education field as the society adds on Rs 20-25 crore investment for expanding the education sector.
In addition to this, the group is also planning to set up a school in Punjab based on the IGSE (International General Certificate of Secondary Education) system.

---

---

---

---

Tribune News Service.
Chandigarh, December 12

Indswift Limited and Mansa Print & publishers Ltd in association with The Tribune organised Painting Competition, which was held at Government Museum and Art Gallery, Sector 10.

More than 500 children students participated from Tricity. The theme for the painting competition was “Your favourite place in city Beautiful”.

The jury included Ravinder Kumar Sharma, Anita Gupta, senior faculty members from Government College of Arts (GCA); Inderjit Gupta, former faculty member from GCA; and Parneet Kaur, an NCERT national award winner. Dr DS Kapoor, principal, GCA, and NPS Randhawa, director, Government Museum and Art Gallery, Sector 10, were the chief guest and guest of honour, respectively The eminent jury had a tough time in short listing winners as there were more than 500 children, who participated in the competition.

A painting on Sukhna Lake by Aashima Shandalaya from Sector 20, Panchkula, bagged the first prize in The Tribune painting competition held at the Government Museum and Art Gallery, Sector 10, here today.

While a painting on Rock Garden by Amanat Singh, a resident of Sector 21-D, bagged the second prize, the third prize went to Bhavika Manchanda from Phase IX, Mohali. Photographs Enclosed:

Ind-Swift group eyes Rs 1,200cr revenues this year

New Delhi /Chandigarh March 23, 2009

Ind-Swift group, a Chandigarh-based research-driven pharmaceutical group with presence across 45 countries, expects to close the current fiscal with collective sales of Rs 1,200 crore from its two firms – Ind-Swift Limited and Ind-Swift Laboratories.The group is expecting a net profit of about Rs 74 crore in the current fiscal from the two companies, besides anticipating a 25 per cent growth in sales during the next financial year.

“In the current fiscal, we are expecting the two firms to have collective sales of Rs 1,200 crore,” Ind Swift Limited MD, Gopal Munjal, told Business Standard. According to Ind-Swift vice-president (finance) Amit Tarfdar, while the group is expecting Ind-Swift Limited to clock revenues of Rs 600 crore, Ind-Swift Laboratories' revenue is likely touch Rs 590 crore. “We are expecting a net profit of Rs 34-35 crore and Rs 38-39 crore from these two companies respectively this financial year,” he said.

Ind-Swift to foray into education sector

Chandigarh  July 15, 2008,

Chandigarh-based Ind-Swift Pharmaceutical (a Fortune 500 company) has forayed into education sector and is planning to set up deemed healthcare university in Una district of Himachal Pradesh with an investment of over Rs 250 crore. The company has already submitted its detailed project report to the Himachal Pradesh government and waiting for its approval. It also plans to set up technical university in Haryana and a deemed university in Punjab. The group plans to invest close to Rs 1,000 crore in five years on setting up educational institutes in these states and Uttarakhand. The company has floated a society called Swift Fundamental Research and Education Society (SFRES), to foray into education. In an interaction with Business Standard, SFRES, President and Managing Director of Ind Swift Ltd, G Munjal, said, "To meet the growing need for quality professionals in the country, we have forayed into education sector by floating a society called SFRES. We have plans to set up Deemed Healthcare University in Himachal Pradesh with an investment of over Rs 250 crore. we have already submitted our plan to the state government and waiting for the necessary clearances. The society will need at least 100 acres of land for setting up the University. "We also plan to promote medical tourism in the state by setting up five- or seven-star hotel, healthcare resort adjoining the University," he added. The group today announced setting up Swift School of Pharmacy at Rajpura, Punjab, to meet the growing need for quality pharmacists in the Pharmaceutical Industry. Talking about Punjab plans, he added, "We have plans to set up a deemed university spread in over 100 acres in Punjab. As far as land is concerned it may be at single location or at different locations." The group has 40 acres in Rajpura and already started Pharmacy College and will very soon start a nursing college. "We plan to set up a deemed university in Punjab. Initially, we will start pharmacy and nursing colleges, and later on add dentistry, engineering, architecture, management and medical colleges at the proposed location," Munjal, said. The pharmaceuticals group also plans to set up professional colleges in other states. We plan to pump in Rs 1,000 crore in five years for setting up educational institutes in other states as well," he added. The company plans to set up technical university in Haryana and also educational institutes in Uttarakhand. The company will fund the project through internal accruals and term-loans. Ind-Swift group is one of the leading pharmaceuticals groups in India with presence in over 45 countries with two listed entities Ind-Swift Ltd and Ind-Swift Laboratories Ltd, and a wholly-owned subsidiary in the US.